A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Journal: Nature Communications

Published: 2020-10-15

DOI: 10.1038/s41467-020-19055-7

Affiliations: 7

Authors: 15

Go to article
Institutions Share
UTMB Health, United States of America (USA) 0.73
Gilead Sciences, Inc., United States of America (USA) 0.20
University of Texas Medical Branch (UTMB), United States of America (USA) 0.07

Return